Raul A M Melo
Overview
Explore the profile of Raul A M Melo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Silva W, Kim H, Undurraga M, Navarro-Cabrera J, Salinas V, Muxi P, et al.
Haematologica
. 2024 Oct;
110(3):795-798.
PMID: 39479861
No abstract available.
2.
Koury L, Kim H, Undurraga M, Navarro-Cabrera J, Salinas V, Muxi P, et al.
Blood
. 2024 May;
144(12):1257-1270.
PMID: 38805638
The introduction of all-trans retinoic acid combined with anthracyclines has significantly improved the outcomes for patients diagnosed with acute promyelocytic leukemia (APL), and this strategy remains the standard of care...
3.
Weinhauser I, Pereira-Martins D, Ortiz C, Silveira D, Simoes L, Bianco T, et al.
Cancers (Basel)
. 2020 Oct;
12(11).
PMID: 33120864
The SLIT-ROBO axis plays an important role in normal stem-cell biology, with possible repercussions on cancer stem cell emergence. Although the Promyelocytic Leukemia (PML) protein can regulate expression in the...
4.
Thome C, Ferreira G, Pereira-Martins D, Augusto Dos Santos G, Ortiz C, de Souza L, et al.
Sci Rep
. 2020 Jun;
10(1):10315.
PMID: 32587277
Non-T cell activation linker (NTAL) is a lipid raft-membrane protein expressed by normal and leukemic cells and involved in cell signaling. In acute promyelocytic leukemia (APL), NTAL depletion from lipid...
5.
Lucena-Araujo A, Coelho-Silva J, Pereira-Martins D, Silveira D, Koury L, Melo R, et al.
Blood
. 2019 Jul;
134(12):951-959.
PMID: 31292112
By combining the analysis of mutations with aberrant expression of genes previously related to poorer prognosis in both acute promyelocytic leukemia (APL) and acute myeloid leukemia, we arrived at an...
6.
Lucena-Araujo A, Pereira-Martins D, Koury L, Franca-Neto P, Coelho-Silva J, de Deus Wagatsuma V, et al.
Blood Adv
. 2018 Jan;
1(21):1807-1814.
PMID: 29296827
Although overexpression of the brain and acute leukemia, cytoplasmic () gene is associated with primary resistant disease and shorter relapse-free, disease-free, and overall survival in different subsets of acute myeloid...
7.
Sanz M, Montesinos P, Kim H, Ruiz-Arguelles G, Undurraga M, Uriarte M, et al.
Ann Hematol
. 2015 May;
94(8):1347-56.
PMID: 25975975
Front-line treatment of acute promyelocytic leukaemia (APL) consists of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy. In this setting, a comparison of idarubicin and daunorubicin has never been carried out....
8.
Rego E, Kim H, Ruiz-Arguelles G, Undurraga M, Uriarte M, Jacomo R, et al.
Blood
. 2013 Jan;
121(11):1935-43.
PMID: 23319575
Thanks to modern treatment with all-trans retinoic acid and chemotherapy, acute promyelocytic leukemia (APL) is now the most curable type of leukemia. However, this progress has not yielded equivalent benefit...
9.
Rego E, Kim H, Ruiz-Arguelles G, Uriarte M, Jacomo R, Gutierrez-Aguirre H, et al.
Hematology
. 2012 Apr;
17 Suppl 1:S36-8.
PMID: 22507775
Objectives: Several clinical trials conducted in Europe and US reported favorable outcomes of patients with APL treated with the combination of all trans retinoic acid (ATRA) and anthracyclines. Nevertheless, the...